1. Home
  2. HXHX vs APVO Comparison

HXHX vs APVO Comparison

Compare HXHX & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

HXHX

Haoxin Holdings Limited Class A Ordinary Shares

HOLD

Current Price

$0.54

Market Cap

8.1M

Sector

Industrials

ML Signal

HOLD

Logo Aptevo Therapeutics Inc.

APVO

Aptevo Therapeutics Inc.

HOLD

Current Price

$7.50

Market Cap

8.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HXHX
APVO
Founded
2003
2016
Country
China
United States
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.1M
8.3M
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
HXHX
APVO
Price
$0.54
$7.50
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
2.7M
38.0K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$3,114,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$1.96
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.33
$0.25
52 Week High
$2.15
$13.11

Technical Indicators

Market Signals
Indicator
HXHX
APVO
Relative Strength Index (RSI) 52.70 54.34
Support Level $0.49 $5.94
Resistance Level $0.55 $7.70
Average True Range (ATR) 0.09 0.55
MACD 0.01 -0.03
Stochastic Oscillator 54.00 80.57

Price Performance

Historical Comparison
HXHX
APVO

About HXHX Haoxin Holdings Limited Class A Ordinary Shares

Haoxin Holdings Ltd is engaged in the logistics industry, including container provider of temperature-controlled truckload service and urban delivery services in China, freight forwarding, cold chain transportation and other businesses. The types of goods involved are all kinds of new energy materials that require low temperature, heat preservation, and constant temperature, electronic products, medicines, meat, fruits, vegetables and others.

About APVO Aptevo Therapeutics Inc.

Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.

Share on Social Networks: